These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks promotes its Earnings ESP tool as a way to identify likely earnings beat candidates, noting that a positive ESP combined with a Zacks Rank of #3 or better historically produced positive surprises 70% of the time and 28.3% annual returns in a 10‑year backtest. It highlights United Therapeutics (UTHR, Zacks Rank #3) with a Most Accurate EPS of $6.49 vs. consensus $6.18 (ESP +4.91%; next report Aug 7, 2024) and Recursion Pharmaceuticals (RXRX, Zacks Rank #2) with a Most Accurate EPS of -$0.33 vs. consensus -$0.35 (ESP +8.02%; next report Aug 13, 2024), implying elevated probabilities of earnings beats for both names.

Analysis

Market structure: Positive Earnings ESP readings (UTHR +4.91% ahead of Aug 7; RXRX +8.02% ahead of Aug 13) favor idiosyncratic upside for those tickers and benefit options sellers if IV collapses after beats. Biotech/medical midcaps and small-cap discovery names will see the largest re-pricing (winners: names with fresh analyst upgrades; losers: heavily shorted or consensus-miss candidates), shifting short-term market share toward names with visible near-term catalysts. Cross-asset impact is concentrated — expect elevated equity vols and option skew in XBI/IBB and issuer-specific names, minimal FX or commodity moves, and modest tightening in high-yield spreads for issuers that materially beat guidance.

Risk assessment: Tail risks include regulatory pricing actions, clinical/regulatory setbacks, or guidance cuts that could trigger >30% drawdowns for small-cap biotechs within days; for UTHR product-concentration and pricing pressure are key low-probability/high-impact risks. Time horizons: immediate (days) dominated by IV and headline risk; short-term (weeks/months) by post-report guidance and analyst revisions; long-term (quarters/years) by pipeline execution and reimbursement trends. Hidden dependencies: consensus-beating probability depends on late analyst revisions — monitor Most Accurate estimate moves 7–14 days pre-report; catalyst list (FDA meetings, trial data) can rapidly reverse sentiment.

Trade implications: Direct plays — size small, event-weighted positions: tactical long RXRX (speculative) and conservative long UTHR with strict risk controls; prefer debit call spreads to limit IV exposure and cost. Pair trades — long RXRX vs short XBI or a negative-ESP small-cap peer to isolate idiosyncratic beat; size hedges 30–50% notional. Options tactics — buy 20–30 delta call spreads expiring 30–90 days post-earnings if IV percentile <60; if IV >60, favor calendar/debit spreads or avoid outright long calls; avoid naked short puts.

Contrarian angles: The ESP backtest (70% when combined with Zacks Rank) is useful but selection-biased — UTHR’s #3 (Hold) weakens the beat conviction relative to RXRX’s #2; the market may underprice RXRX’s optionality if IV is suppressed. Reaction may be overdone in names with large short interest where a small beat can force squeeze; conversely, crowded long names can see amplified sell-the-news. Historical parallels: small-cap biotech earnings seasons often see 20–50% swings around earnings — size positions to absorb a single-event IV crush and avoid levering into earnings unless with defined-risk options.

Key Decisions for Investors

• Establish a tactical 1–2% long position in RXRX equity or buy a 20–30 delta call spread expiring 60–120 days (cap max loss to ~100% of position) ahead of Aug 13 earnings; increase to 2–3% only on a confirmed post-earnings analyst upgrade within 2 weeks.
• Establish a conservative 1% position in UTHR via a Sep debit call spread (30–60 day tenor) rather than outright stock ahead of Aug 7; if implied vol >60th percentile, shift to a wider spread or wait for post-earnings IV collapse to buy calls.
• Implement a relative-value pair: long RXRX (1%) vs short XBI (0.5%) to hedge market beta between now and Aug 20; unwind or rebalance within 10 trading days post-RXRX print.
• Monitor three thresholds 7–14 days pre-earnings before adding risk: (1) Most Accurate estimate revisions (any upward rev >5% increases conviction), (2) front-month IV percentile (if >60, avoid naked longs), (3) short interest >15% (expect squeeze risk).
• Avoid selling naked puts on these tickers; instead, if comfortable collecting premium, sell OTM put-credit spreads sized to 0.5–1% max portfolio risk with expiries 30–60 days and delta no lower than 0.20.